Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS
Other: Grapefruit juice
Drug: Nelfinavir
Drug: Atazanavir
Drug: Ritonavir

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 44

Registration Number: NCT02257008

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIRT 2584 XX - single dose
Drug: BIRT 2584 XX - multiple escalating dose
Drug: Placebo
Other: high caloric meal

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 74

Registration Number: NCT02256761

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIRT 2584 XX
Drug: Midazolam

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02256748

Study to Evaluate the Effect Single and Multiple Oral Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIRT 2584 XX
Drug: Amitriptyline

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02256878

Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS
Drug: Low dose of ritonavir
Drug: Tipranavir
Drug: High dose of ritonavir

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02257021

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS
Drug: Ritonavir (RTV)
Drug: Kaletra®

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02256826

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS
Drug: Combivir®
Drug: Ritonavir

First Posted Date: 2014-10-06

Last Posted Date: 2014-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 51

Registration Number: NCT02256774

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BEA 2180 BR solution for infusion
Drug: Placebo
Drug: BEA 2180 BR solution for inhalation
Device: Respimat®

First Posted Date: 2014-10-02

Last Posted Date: 2014-10-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 71

Registration Number: NCT02254720

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS
Drug: PEG 400

First Posted Date: 2014-10-02

Last Posted Date: 2014-10-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 54

Registration Number: NCT02254538

Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Phase 1

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Placebo
Drug: BILB 1941 ZW

First Posted Date: 2014-10-02

Last Posted Date: 2014-10-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02254707

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy